Navigation Links
SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR-NCI-EORTC International Conference
Date:10/17/2007

DUBLIN, Calif., Oct. 17 /PRNewswire-FirstCall/ -- SuperGen Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, today announced that multiple abstracts have been accepted for poster presentations at the AACR-NCI-EORTC International Conference from Oct. 22-26 at the Moscone Center in San Francisco.

The poster presentations will focus on data concerning many of SuperGen's current oncology programs including the lead clinical compound, MP470, and its ability to suppress the repair of double stranded DNA breaks following treatment with DNA-damaging agents.

In addition to the poster presentations listed below, data on SuperGen's hypomethylating agent, S110, will be presented by Dr. Peter A. Jones on Wednesday, Oct. 24 at 8:00 a.m. in Plenary Session 3: Epigenetic Targets.

SuperGen's schedule of presentations is as follows:

Poster

Date Time (PDT) Abstract # and Title Number/Session

Tuesday, 12:30 p.m.- # 1026 - MP470 #A173

Oct. 23 2:30 p.m. suppresses repair of

double-strand breaks Poster Session A

5:30 p.m.- following treatment

7:30 p.m. with DNA-damaging

agents

Wednesday, 12:30 p.m.- # 1038 - The #B140

Oct. 24 2:30 p.m. decitabine-derived

demethylating Poster Session B

5:30 p.m.- dinucleotide, S110

7:30 p.m. shows improved

activity due to

increased drug

delivery and

stability

Thursday, 12:30 p.m.- # 907 - Effect of #C200

Oct. 25 2:30 p.m. small molecule

inhibitors of JAK2 Poster Session C

5:30 p.m.- kinase on modulating

7:30 p.m. signaling cascades

downstream of

cytokine receptors

Thursday, 12:30 p.m.- # 985 - A small #C208

Oct. 25 2:30 p.m. molecule inhibitor of

Pim-1 kinase with Poster Session C

5:30 p.m.- activity in both

7:30 p.m. hematological and

solid tumor

malignancies

About SuperGen

Based in Dublin, Calif., SuperGen, Inc. is a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For more information about SuperGen, please visit http://www.supergen.com.

Forward-Looking Statements

This news release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that may cause actual results to differ materially from the results discussed in these statements. Factors that might cause the company's results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the ability to discover, develop and move target compounds into clinical development and other risks and uncertainties detailed from time to time in the company's filings with the Securities and Exchange Commission including its most recently filed Form 10-Q and 10-K. SuperGen, Inc. undertakes no duty to update any of these forward-looking statements to conform them to actual results.

Contacts

Timothy L. Enns Mary M. Vegh

SuperGen, Inc. SuperGen, Inc.

SVP, Corporate Communications Manager, Investor Relations

& Business Development Tel: (925) 560-2845

Tel: (925) 560-0100 E-mail: mary.vegh@supergen.com

E-mail: tenns@supergen.com


'/>"/>
SOURCE SuperGen Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Chennai AIDS Campaign Highlights The Social Neglect Faced By Victims
2. Benzene Slick In China Highlights Water Pollution
3. India To Highlight Its Scientific Achievements
4. Homecare Association Highlights Cost-Effectiveness of Medicare and Medicaid
5. India To Highlight The Potential Role Of Ayurveda In London
6. Study Highlights Appetite Regulation Pathway, New Hope for Weight Loss
7. Study Highlights How Bacteria Respond To Changes In Environment
8. Drug Action Week to Highlight Effects of Alcohol
9. Clinton, Gates Highlight Treatment, Discrimination of AIDS
10. Highlights from World Transplant Congress
11. Latest IPCC Report Highlights Need for Integrated Climate/human Behavior Models
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... (PRWEB) , ... April 28, 2016 , ... ... which is has been collaborating with doctors and hospitals to make transformative changes ... the world’s leading cell therapy minds this week in discussing breakthroughs in cellular ...
(Date:4/28/2016)... ... ... Medical Card reminds us that May is National Stroke Awareness Month. According to the ... death in the United States; someone has one every 40 seconds. Annually, almost 800,000 ... years old. A stroke is when blood flow to the brain is blocked or ...
(Date:4/28/2016)... ... 28, 2016 , ... April, 28, 2016 – Magee Rehabilitation ... Medicine and Rehabilitation by Philadelphia Magazine. , Philadelphia Magazine’s annual Top Doctors list ... and medical leadership across the country. These select individuals nominate outstanding physicians in ...
(Date:4/28/2016)... ... , ... Denise McCormick Baich had written poetry dating back to her childhood, but after several ... tsunami and took on a more spiritual tone. The desire to put the words on ... it than just file it away. Friends would ask her how she wrote such wonderful ...
(Date:4/28/2016)... ... April 28, 2016 , ... Prescription ... co-operative bankruptcy to receive their prescription medications through America’s fastest-growing pharmacy program. ... medications from over 180 American pharmaceutical companies for $35 per month, per ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... , April 27, 2016 ... a developer of a new generation of drugs ... overall survival results for Paclical/Apealea in the Phase ... patients with epithelial ovarian cancer. These preliminary results ... in combination with carboplatin versus Taxol in combination ...
(Date:4/26/2016)... Diplomat Pharmacy, Inc. (NYSE: DPLO) is pleased ... Pharm D., to Vice President of Education and Quality. ... will continue to lead and oversee Diplomat University, an ... and training to Diplomat employees and external professionals on ... also houses the quality assurance department, which focuses on ...
(Date:4/26/2016)... -- Research and Markets has announced the addition ... the Biological Medicine Industry in China 2016"  report to ... financial assessment and credit risk of the biological medicine ... provides readers with an in-depth understanding of the industry ... aware of. It considers current and future drivers, challenge ...
Breaking Medicine Technology: